E. Masala

发表

Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia

V. Santini, A. Sanna, A. Gozzini, 2017, Haematologica.

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

P. Fenaux, M. Fontenay, Sophie Park, 2016, Haematologica.

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

Sheng Wei, J. Maciejewski, P. Fenaux, 2017, Haematologica.

Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells.

D. Nosi, A. Bosi, S. Zecchi, 2012, Leukemia research.

The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes

G. Mufti, Sheng Wei, J. Maciejewski, 2015 .

Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.

B. Fridley, P. Fenaux, J. Pinilla-Ibarz, 2021, Blood advances.

Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.

A. Bosi, V. Santini, A. Sanna, 2012, Leukemia research.

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

B. Fridley, Sheng Wei, P. Fenaux, 2018, The Lancet. Haematology.

The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction

M. Lulli, N. Mazure, P. Dello Sbarba, 2017, Stem cells international.

Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures

A. Arcangeli, S. Pillozzi, V. Santini, 2018, Oncotarget.

Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3

V. Santini, A. Valencia, A. Sanna, 2013, Epigenetics.

Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules.

L. Formigli, F. Francini, R. Squecco, 2012, European journal of pharmacology.

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

M. Voso, F. Canzian, A. Bosi, 2013, Leukemia.

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Omar Abdel-Wahab, Valeria Santini, Tingting Qin, 2015, The Journal of clinical investigation.

Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients

A. Bosi, R. Caporale, V. Santini, 2012, Clinical Cancer Research.

Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?

V. Santini, F. Olivieri, A. Giuliani, 2020, Frontiers in Oncology.